Spdr S&P Biotech Etf (XBI-N) Stock Predictions - Stockchase
WATCH LIST
4
Spdr S&P Biotech Etf (XBI-N)

ON STOCKCHASE SINCE Jun 2016

E.T.F.'s

Spdr S&P Biotech Etf

XBI-N

3 watching          
Join the Discussion

Spdr S&P Biotech Etf (XBI-N) SAVE Apr, 22, 2019, 10:45 am

84.64 0.01 (0.01%)

What the experts are saying about XBI-N



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
Spdr S&P Biotech Etf(XBI-N) 

October 10, 2018

(A Top Pick October 10/17 Up 0.2%) He stepped out of this a month after they recommended it. It broke down on the relative strength measure and has not done much else since. He likes the healthcare space still however.      

E.T.F.'s
0 0 0 0 0
0 comments

(A Top Pick October 10/17 Up 0.2%) He stepped out of this a month after they recommended it. It broke down on the relative strength measure and has not done much else since. He likes the healthcare space still however.      

E.T.F.'s
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$85.440
Owned Owned
No

TOP PICK
Spdr S&P Biotech Etf(XBI-N) 

October 10, 2017

This is equal weighted, so you are getting a split between the big hefty diversifieds. M&A, which has been highlighted by Gilead, is definitely driving the sector now. At the same time, you are getting the basket approach of the big guys, you are incorporating the small guys as take-out targets that give you the big premium. There is a slightly softer regulatory environment where more drugs are making it to market.

E.T.F.'s
0 0 0 0 0
0 comments

This is equal weighted, so you are getting a split between the big hefty diversifieds. M&A, which has been highlighted by Gilead, is definitely driving the sector now. At the same time, you are getting the basket approach of the big guys, you are incorporating the small guys as take-out targets that give you the big premium. There is a slightly softer regulatory environment where more drugs are making it to market.

E.T.F.'s
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$87.630
Owned Owned
Yes

COMMENT

He likes biotech. This ETF will be an equal weight of all the names, so you are going to get some of the smaller cap names, which will have benefited you. Thinks there is lots of growth left in this space.

E.T.F.'s
0 0 0 0 0
0 comments

He likes biotech. This ETF will be an equal weight of all the names, so you are going to get some of the smaller cap names, which will have benefited you. Thinks there is lots of growth left in this space.

E.T.F.'s
0 0 0 0 0
0 comments
Stan Wong

Director &, Private Wealth Manag...

Price Price
$78.220
Owned Owned
No

BUY

Biotechs have a strong seasonality that starts in July, so right about now you should get a nice move. It has a historical 100% gain potential in July. Believes that healthcare and biotech specifically is probably the next thing that is going to move the needle for humanity, so he would accumulate this on a long-term basis. Owning this for 10 years will be a good thing.

E.T.F.'s
0 0 0 0 0
0 comments

Biotechs have a strong seasonality that starts in July, so right about now you should get a nice move. It has a historical 100% gain potential in July. Believes that healthcare and biotech specifically is probably the next thing that is going to move the needle for humanity, so he would accumulate this on a long-term basis. Owning this for 10 years will be a good thing.

E.T.F.'s
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$54.080
Owned Owned
Unknown

Showing 1 to 4 of 4 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days